Yazar "Yolbaş, Servet" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Carotid artery stiffness in Behçet's disease(2017) Yolbaş, Servet; Gözel, Nevzat; Dağlı, Mustafa Necati; Koca, Süleyman Serdar; Dönder, EmirObjective: Increased carotid arterial stiffness (CAS) is a predictor of subclinical early atherosclerosis as well as carotid intima-media thickness (cIMT). We aimed to determine CAS and cIMT in Behçet's disease (BD).Material and Methods: BD (n=49) and rheumatoid arthritis (RA) (n=64) patients and healthy controls (HC) (n=40) were included in the study. cIMT was measured. CAS indices, including arterial compliance (AC), arterial distensibility (AD), Young's elastic modulus (YEM), Peterson's elastic modulus (Ep), and ? stiffness index (?SI) were measured based on the diameter-pressure relationship.Results: When compared to the HC group, the mean cIMT was significantly higher in the RA group (p=0.033), but it was not higher in the BD group. The CAS indices, including AD, AC, Ep, and ?SI were not significantly different among the study groups. Moreover, the cIMT and CAS indices were not significantly different between active (n=20) and inactive BD patients, and these indices were not correlated with the scores of disease activity. AD, AC and Ep were significantly lower in the BD patients with a positive pathergy reaction than in those with a negative reaction.Conclusion: These results suggest that BD does not directly lead to arterial stiffness or to an increase in cIMT.Öğe The frequency of hepatitis B virus reactivation in patients receiving anti-TNF treatment: A single center, retrospective study(2024) Keser, Muhammed Furkan; Erdogan, Mehmet Ali; Bahçecioğlu, Ömer Faruk; Seçkin, Yüksel; Yolbaş, Servet; Yıldırım, Tülay; Yıldırım, OğuzhanAim: The equilibrium between the host immune response counter the hepatitis B virus (HBV) and the amount of viral replication is a crucial factor in the pathogenesis of HBVassociated liver disease. Tumor necrosis factor-alpha (TNF-?) is a considerable proinflammatory and immune regulatory cytokine in the pathogenesis of various inflammatory and autoimmune conditions. There is no consensus on using antiviral prophylaxis treatments in cases who have been exposed to hepatitis B but have not become chronically ill, and are thus planned to receive anti-TNF-? treatment. The aim of this study is to determine the frequency of reactivation after anti-TNF treatment in cases with isolated anti-HBc total positivity who have been exposed to hepatitis B virus. Materials and Methods: Serological HBV infection markers (HBsAg, anti-HBc IgG and anti-HBs) of 1467 adult cases who received anti-TNF therapy for the indications of various rheumatological diseases in the rheumatology and physical therapy clinics between the years 2010-2021 were retrospectively screened using the hospital’s electronic information system. Results: 140 rheumatologic disease cases who took a TNF-? inhibitor (infliximab, adalimumab, etanercept, golimumab, certolizumab) treatment were included in this study. Before the cases were started on TNF-? treatment, all cases were anti-HBc total positive, 110 were anti-HBs positive, 30 were anti-HBs negative, and 4 were HbsAg positive and HBV-DNA negative. The median pre-treatment anti-HBc total and anti-HBs values of the cases were 5.6 IU/L and 79.29 IU/L, respectively. No HBV reactivation was observed in any of the 140 cases after a median follow-up duration of 71.5 (min. 8, max. 185) months. Conclusion: In conclusion, HBV reactivation was not detected in any of the anti-HBc positive cases included in this study, which suggest that anti-HBc positive cases can be followed up with close follow-up without starting them on anti-TNF therapies and antiviral prophylaxis.Öğe The inhibition of Src kinase suppresses the production of matrix metalloproteinases in from synovial fibroblasts and inhibits MAPK and STATs pathways(2021) Yalçın Kehribar, Demet; Özgen, Metin; Yolbaş, Servet; Yıldırım, Ahmet; Türkmen, Neşe Başak; Onalan, Ebru; Çiftci, Osman; Özercan, İbrahim Hanifi; Koca, Süleyman S.Abstract: Background/aim: The purpose of this study was to investigate the antiarthritic potentials of the inhibition of Src kinase in vivo and in vitro settings. Materials and methods: Arthritis was induced by intradermal injection of chicken type II collagen combined with incomplete Freund’s adjuvant (collagen induced arthritis [CIA] model) in Wistar albino rats. One day after the onset of arthritis, dasatinib, a potent Src kinase inhibitor, (5 mg/kg/day) was given via oral gavage. Tissue Src, Fyn, MAPK and STAT mRNA expressions were determined by real-time polymerase chain reaction. On the other hand, fibroblast like synoviocytes (FLSs) were harvested patients with rheumatoid arthritis (RA) undergoing surgical knee joint replacement. FLSs were stimulated with cytokines and dasatinib was added in different concentrations. MMP –1, –3, and –13 levels in FLSs culture were determined by ELISA. Results: The tissue mRNA expressions of Src, Fyn, MAPK and STATs were increased in the arthritis CIA group compared to the control group. Their mRNA expressions in the CIA + dasatinib group were decreased and similar in the control group. In in vitro setting, MMP –1, –3, and –13 expressions from FLSs induced by IL-1? and TNF-? were increased, while dasatinib suppressed their productions from FLSs. Conclusion: The present study shows that the inhibition of Src kinase has antiarthritic potentials in both in vivo and in vitro settings. Src kinase inhibition may be candidate to further research in human RA. Key words: Rheumatoid arthritis, collagen induced arthritis, src kinase, matrix metalloproteinaseÖğe İzole Santral Sinir Sistemi Tutulumu Gösteren Bir Rosai-Dorfman Hastalığı Olgusu(2024) Algül, Fatma Ebru; Erdem, Begüm Yeni; Yeğen, Gülçin; Yolbaş, Servet[Abstract Not Available]Öğe Seronegatif ve Seropozitif Romatoid Artritli HastalardaAbatasept Tedavisinin Etkinliği(2020) Karataş, Ahmet; Yolbaş, Servet; Öz, Burak; Gözel, Nevzat; Sağır, Rabia Pişkin; Gur, MustafaAmaç: Bu çalışmada, seronegatif ve seropozitif romatoid artrit (RA) tanılı hastalarda abatasept tedavisinin etkinlik bakımından karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Çalışmaya Fırat Üniversitesi Romatoloji bölümünce 2014 - 2017 yılları arasında takip edilen, 2010 Amerikan Romatoloji Cemiyeti (ACR) kriterlerine göre RA tanısı konulmuş ve abatasept tedavisi almış olan hastalar dahil edildi. RF ve/veya anti-CCP oto-antikor pozitifliği olanlar seropozitif RA, negatif olanlar ise seronegatif RA olarak gruplandırıldı. Hastalık aktivite skoru (DAS) 28-CRP, klinik hastalık aktivite indeksi (CDAI), sağlık değerlendirme anketi (HAQ) ve görsel analog skala (VAS) skorlamaları ile laboratuvar verileri geriye dönük olarak hasta dosyalarından taranarak kaydedildi. Bulgular: Abatasept kullanan hastalarda %37.1 (n=13) RF negatifliği, %62.9 (n=22) RF pozitifliği saptandı. Abatasept kullanan hastaların %34.2’ sinde (n=12) anti-CCP negatif, %65.8’sinde (n=23) anti-CCP pozitif olarak saptandı. Abatasept tedavisine devam eden hasta sayısı toplam %57.1 (n=20) olarak tespit edildi. RF pozitif hastalarda tedaviye devam oranı %59.1 iken, negatif hastalarda bu oran %53.8 idi (P=0.762). Anti-CCP pozitif hastalarda tedaviye devam oranı %70 iken, negatif hastalarda bu oran %50 idi (P=0.284). Seropozitifliğin ilaca devam oranları üzerine etkisi istatistiksel olarak anlamlı değildi. DAS28-CRP, CDAİ, VAS-ağrı, VAS-global, VAS-hekim ve HAQ skorlarında iki grup arasında istatistiksel olarak anlamlı bir farklılık yoktu. Sonuç: Bu çalışmada seropozitif ve seronegatif RA hastalarında abatasept tedavisinin etkinliğinin benzer olduğu saptandı.Öğe Vildagliptin treatment on the portal venous pressure and hepatosteatosis inpatients with type 2 diabetes mellitus(Aves, buyukdere cad 105-9, mecıdıyekoy, sıslı, ıstanbul 34394, turkey, 2018) Yolbaş, ServetObjective: This study investigated how vildagliptin (a di-peptidyl peptidase 4 inhibitor) affects portal vein pressure and hepatosteatosis in patients with type 2 diabetes mellitus. Methods: This cross-sectional study evaluated the use of specific drugs for at least 3 months on two groups of type 2 diabetes mellitus cases. Group 1 used metformin and gliclazide, Group 2 used the same amounts of metformin and gliclazide, with the addition of vildagliptin. Using Doppler ultrasound, all cases were measured for portal vein flow velocity, portal vein flow and portal vein diameter. Degree of hepatosteatosis was also recorded. Results: A total of 97 patients completed the study. The study finished with 49 type 2 DM patients in Group1 (20 men, 29 women) and 48 patients in Group2 (20 men, 28 women. No significant difference was found in term of age, gender, BMI, HbA1c, mean arterial pressure, LDL-C, HDL-C or triglyceride levels in two groups. Portal vein flow velocity, portal vein flow volume, and portal vein diameter of all cases were measured by Doppler ultrasound in both groups. No significant difference was found between the groups (respectively p=0.92,p=0.60, p=0.92). There was no significant difference between groups regarding to ultrasonographic grading of hepatosteatosis Conclusion: Treating type 2 diabetes mellitus patients with vildagliptin for had no effect on portal vein hemodynamics and hepatosteatosis as assessed with Doppler ultrasound. Further long-term studies with better evaluation methods are needed to demonstrate any expected beneficial effect of vildagliptin on portal hemodynamics and hepatosteatosis.
